Motus GI Holdings (MOTS) Forecasted to Earn Q2 2018 Earnings of ($0.27) Per Share

Motus GI Holdings (NASDAQ:MOTS) – Research analysts at Piper Jaffray issued their Q2 2018 earnings per share estimates for shares of Motus GI in a report issued on Tuesday, May 15th. Piper Jaffray analyst M. O’brien forecasts that the company will post earnings per share of ($0.27) for the quarter. Piper Jaffray currently has a “Overweight” rating and a $7.00 target price on the stock. Piper Jaffray also issued estimates for Motus GI’s Q3 2018 earnings at ($0.27) EPS, Q4 2018 earnings at ($0.27) EPS, FY2018 earnings at ($1.12) EPS, Q1 2019 earnings at ($0.32) EPS, Q2 2019 earnings at ($0.27) EPS, Q3 2019 earnings at ($0.22) EPS, Q4 2019 earnings at ($0.13) EPS and FY2019 earnings at ($0.88) EPS.

MOTS has been the topic of a number of other reports. ValuEngine upgraded shares of Motus GI from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Oppenheimer began coverage on shares of Motus GI in a report on Monday, March 12th. They issued an “outperform” rating and a $7.00 price objective on the stock.

Motus GI opened at $5.19 on Friday, according to MarketBeat. Motus GI has a 12-month low of $4.61 and a 12-month high of $4.79.

An institutional investor recently bought a new position in Motus GI stock. Hilltop Holdings Inc. acquired a new stake in Motus GI Holdings (NASDAQ:MOTS) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 112,100 shares of the company’s stock, valued at approximately $502,000. Hilltop Holdings Inc. owned about 0.72% of Motus GI as of its most recent SEC filing. Institutional investors and hedge funds own 0.01% of the company’s stock.

Motus GI Company Profile

Motus GI Holdings, Inc, a medical technology company, focuses on the development and commercialization of the Pure-Vu System. Its Pure-Vu System is designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.

Earnings History and Estimates for Motus GI (NASDAQ:MOTS)

Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with's FREE daily email newsletter.

Leave a Reply